Year: 2025
Type: article
Abstract: Background and objectives. Recurrent meningiomas present substantial clinical challenges due to their aggressive behavior and resistance to standard treatments, particularly in higher-grade tumors. Advances in understanding the genetic, molecular, and epigenetic landscape have provided insights into mechanisms of recurrence, including NF2 and non-NF2 mutations, with important implications for prognosis and the development of biomarkers. Materials and methods. This narrative review synthesizes current evidence from clinical, translational, and observational studies focusing on genetic alterations, epigenetic changes, diagnostic modalities, and therapeutic interventions in recurrent meningioma. Results. Biomarkers derived from genetic and molecular profiling, including NF2 and non-NF2 mutations, demonstrate potential for predicting tumor progression and prognosis. The diagnostic limitations of traditional imaging modalities, such as MRI and CT, are highlighted, underscoring the need for advanced imaging techniques to improve diagnostic accuracy. Systemic therapies, including immunotherapy and targeted therapies, show potential but remain largely experimental, with inconsistent efficacy. Conclusions. Current evidence emphasizes the importance of integrating molecular biomarkers and advanced diagnostic tools to refine prognostic assessment and guide therapeutic strategies. Further research is required to validate biomarkers, optimize systemic therapy, and advance personalized care to improve outcomes for patients with recurrent meningiomas.
Source: Romanian Journal of Neurology
Authors: Yuli Felistia, Salma Dhiya Rachmadani, Muhammad Miftahussurur
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4417539732